Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
38 studies found for:    "Alveolar soft part sarcoma"
Show Display Options
Rank Status Study
21 Terminated Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma
Condition: Sarcoma
Interventions: Drug: doxorubicin hydrochloride;   Drug: trabectedin;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment
22 Unknown  Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma
Conditions: Childhood Malignant Fibrous Histiocytoma of Bone;   Sarcoma
Interventions: Drug: doxorubicin hydrochloride;   Drug: ifosfamide;   Procedure: adjuvant therapy;   Procedure: conventional surgery;   Procedure: neoadjuvant therapy;   Radiation: radiation therapy
23 Terminated
Has Results
Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Stage IB, Stage II, or Stage III Soft Tissue Sarcoma
Condition: Sarcoma
Interventions: Genetic: gene expression analysis;   Genetic: polymerase chain reaction;   Genetic: western blotting;   Procedure: neoadjuvant therapy;   Procedure: therapeutic conventional surgery;   Radiation: intensity-modulated radiation therapy
24 Completed BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors
Conditions: Breast Cancer;   Endometrial Cancer;   Head and Neck Cancer;   Melanoma (Skin);   Ovarian Cancer;   Sarcoma
Interventions: Drug: BI 2536;   Other: high performance liquid chromatography;   Other: mass spectrometry;   Other: pharmacological study
25 Completed
Has Results
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
Conditions: Adult Malignant Fibrous Histiocytoma of Bone;   Desmoid Tumor;   Endometrial Cancer;   Ovarian Cancer;   Sarcoma;   Small Intestine Cancer
Intervention: Drug: sunitinib malate
26 Completed Radiation Therapy in Treating Patients Who Have Undergone Surgery for Soft Tissue Sarcoma of the Arms, Hands, Legs, or Feet
Condition: Sarcoma
Interventions: Procedure: adjuvant therapy;   Radiation: radiation therapy
27 Unknown  Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma
Conditions: Ovarian Cancer;   Sarcoma;   Small Intestine Cancer
Interventions: Drug: brostallicin;   Drug: doxorubicin hydrochloride
28 Completed Liposomal Doxorubicin Plus Ifosfamide in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma
Condition: Sarcoma
Interventions: Drug: ifosfamide;   Drug: pegylated liposomal doxorubicin hydrochloride
29 Completed STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma
Conditions: Endometrial Cancer;   Gastrointestinal Stromal Tumor;   Ovarian Cancer;   Sarcoma;   Small Intestine Cancer
Intervention: Drug: imatinib mesylate
30 Completed Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma
Conditions: Brain and Central Nervous System Tumors;   Endometrial Cancer;   Gastrointestinal Stromal Tumor;   Ovarian Cancer;   Sarcoma;   Small Intestine Cancer
Intervention: Drug: trabectedin
31 Unknown  Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma
Conditions: Endometrial Cancer;   Ovarian Cancer;   Sarcoma
Intervention: Drug: temozolomide
32 Completed Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma
Conditions: Endometrial Cancer;   Kidney Cancer;   Ovarian Cancer;   Pheochromocytoma;   Sarcoma
Interventions: Biological: filgrastim;   Drug: doxorubicin hydrochloride;   Drug: ifosfamide;   Drug: isolated perfusion;   Procedure: adjuvant therapy;   Procedure: conventional surgery;   Radiation: radiation therapy
33 Terminated
Has Results
Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer
Condition: Cancer
Interventions: Drug: cyproheptadine hydrochloride;   Other: placebo
34 Withdrawn Glutamine in Preventing Oral Mucositis in Patients Receiving Chemotherapy for Sarcoma
Conditions: Childhood Malignant Fibrous Histiocytoma of Bone;   Sarcoma
Interventions: Drug: glutamine;   Procedure: chemoprotection;   Procedure: management of therapy complications;   Procedure: therapeutic nutritional supplementation
35 Completed Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma
Conditions: Childhood Malignant Fibrous Histiocytoma of Bone;   Sarcoma
Intervention: Drug: imatinib mesylate
36 Completed Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors
Conditions: Ovarian Cancer;   Sarcoma;   Small Intestine Cancer
Interventions: Biological: dactinomycin;   Biological: filgrastim;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: epirubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: vincristine sulfate;   Procedure: peripheral blood stem cell transplantation;   Radiation: radiation therapy
37 Completed Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma
Conditions: Childhood Malignant Fibrous Histiocytoma of Bone;   Sarcoma
Interventions: Biological: dactinomycin;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: epirubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: vincristine sulfate;   Procedure: adjuvant therapy;   Procedure: conventional surgery;   Procedure: neoadjuvant therapy;   Radiation: brachytherapy;   Radiation: radiation therapy
38 Active, not recruiting Trial of Dasatinib in Advanced Sarcomas
Conditions: Rhabdomyosarcoma;   Malignant Peripheral Nerve Sheath Tumors;   Chondrosarcoma;   Sarcoma, Ewing's;   Sarcoma, Alveolar Soft Part;   Chordoma;   Epithelioid Sarcoma;   Giant Cell Tumor of Bone;   Hemangiopericytoma;   Gastrointestinal Stromal Tumor (GIST)
Intervention: Drug: Dasatinib

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-38) Next Page   
Study has passed its completion date and status has not been verified in more than two years.